Akso Health Group
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AHG research report →
Price Chart
About the company
Akso Health Group, together with its subsidiaries, operates a social e-commerce mobile platform in the People’s Republic of China. It operates Xiaobai Maimai App, a social e-commerce mobile platform that offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appliances, and cost-saving promotions at petrol gas stations. The company also sells medical devices, such as defibrillators and anesthesia laryngoscopes.
- CEO
- Yilin Wang
- IPO
- 2017
- Employees
- 12
- HQ
- Qingdao, SD, CN
Get TickerSpark's AI analysis on AHG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $871.12M
- P/E
- -3.86
- Fwd P/E
- 0.25
- PEG
- -0.04
- P/S
- 61.11
- P/B
- 4.07
- EV/EBITDA
- -405.90
- Div Yield
- 0.00%
- Gross Margin
- -3.93%
- Op Margin
- -721.63%
- Net Margin
- -667.88%
- ROE
- -50.15%
- ROIC
- -56.74%
Latest fiscal year · YoY change
- Revenue
- $13.83M-6.4%
- Gross Profit
- $-11,315+96.0%
- Op Income
- $-4,000,056
- Net Income
- $-18,671,610+86.2%
- EPS
- $-0.03+93.8%
- OCF Growth
- -1186.6%
- FCF Growth
- -18527.4%
- 52W High
- $2.50
- 52W Low
- $0.96
- 50D MA
- $1.41
- 200D MA
- $1.62
- Beta
- -1.01
- RSI (14)
- 33
- Avg Volume
- 13.49K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hexindai reported a sharp year-over-year revenue decline as its P2P business weakened, but management said it is transitioning toward a loan assistance model backed by institutional funding.· September 18, 2019
- Net revenue was $4.9 million, down 90.5% year over year, while net loss was $7.2 million versus net income of $29.7 million a year ago.
- Loan volume facilitated through the P2P marketplace was $28.2 million, down from $0.5 billion in the prior-year quarter.
- Management said the quarter was a transition period and that loan assistance is intended to become the main growth driver alongside P2P.
- Institutional funding represented about 20% of total loans facilitated in the quarter; management expects about 80% in calendar 2020.
- The company had repurchased nearly 1.2 million ADS for about $4 million as of June 30.
First-quarter fiscal 2020 net revenue was $4.9 million, down 90.5% from the same period last year. P2P loan volume facilitated was $28.2 million, or RMB0.2 billion, versus $0.5 billion, or RMB2.9 billion, a year earlier. Operating costs and expenses were $12.6 million, down 18.9%; sales and marketing was $7.5 million, down 35.5%; service and development was $1.9 million, up 42.3%; G&A was $2.3 million, flat; finance costs were $0.6 million versus nil last year. Net loss was $7.2 million versus net income of $29.7 million last year; basic and diluted loss per share were $0.15 versus basic EPS of $0.62 and diluted EPS of $0.56. Adjusted net loss was $7 million versus adjusted net income of $29.9 million, and adjusted EBIT was a loss of $5.8 million versus $36.6 million last year. On a sequential basis, net revenue increased 8.6%. Management said institutional partners funded about 20% of loans facilitated in the quarter and expects about 80% to be funded by institutions in calendar 2020.
The CEO framed the quarter as the start of a transition period under an uncertain regulatory backdrop for P2P lending. He said Hexindai is strategically repositioning toward a loan assistance business, using its borrower-acquisition, risk-management, and operating capabilities to serve institutional partners and diversify funding sources. His tone was confident and forward-looking, emphasizing that the new model should support long-term sustainable growth regardless of how the P2P regulatory environment evolves.
The CFO emphasized that the quarter reflected both declining P2P activity and early progress in the new model. She cited $4.9 million of net revenue, $12.6 million of operating costs and expenses, and a $7.2 million net loss, while noting cost discipline in sales and marketing and a rise in service and development spend tied to employees. She also highlighted the share repurchase program, saying the company had repurchased nearly 1.2 million ADS for about $4 million at an average price of $3.4 per share.
Analyst questions focused on borrower mix, the rationale for loan assistance versus P2P, share repurchases, and the timing/compliance implications of regulators linking P2P platforms to the central bank credit system. Management said 42% of borrowers were acquired online and 58% offline, and that online share should rise as loan assistance scales and microfinance loans, which are acquired purely online, become a larger part of volume. On regulation, management said it had connected with Baihang Credit in January and would keep sharing credit data, describing this as supportive of compliance and credit assessment. On buybacks, management said repurchases depend on share price, trading volume, market conditions, working capital, and business conditions rather than a fixed price target.
The positive case from the call is that Hexindai is already showing early traction with institutional funding partners, including Bohai International Trust, Kunming Aotou, and Phoenix Finance. Management believes the loan assistance model reduces regulatory uncertainty, broadens funding sources, and can leverage existing underwriting and borrower-acquisition capabilities. The company also pointed to sequential revenue growth of 8.6% and expects a much higher share of institutional funding in 2020.
The main risk is that the legacy P2P business is still shrinking sharply, with revenue down 90.5% year over year and loan volume falling dramatically. Management said the ramp-up in loan assistance was not fast enough to offset the P2P decline, and future performance still depends on building institutional funding at scale. Analysts also pressed on regulatory timing and compliance, underscoring that the industry backdrop remains uncertain and central to the investment case.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.0%
- Shares Outstanding
- 854.04M
- Float Shares
- 10.42M
of shares held by institutions
5 13F filers
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 26 | Xie Zhongliang | other | 0 |
| Mar 30, 26 | Xu Jianqiang | other | 0 |
| Mar 27, 26 | Liu Wenjuan | other | 0 |
| Mar 18, 26 | Brown Stephen P | other | 0 |
| Mar 18, 26 | Wang Yilin | other | 0 |
| Mar 18, 26 | Liu Zhe | other | 0 |
| Mar 26, 09 | TOUPS JOHN M | other | 2,000 |
| Oct 28, 08 | PAYSON NORMAN C MD | other | 3,000 |
| Oct 28, 08 | Monast William E | other | 13,040 |
| Oct 28, 08 | Monast William E | other | 5,267 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AHG coverage
Recent articles, reports, and earnings notes.
No research on AHG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AHG report →AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology
prnewswire.com · Apr 27
Akso Health Group (NASDAQ:AHG) Stock Price Down 5.3% – Time to Sell?
defenseworld.net · Apr 12
Treasure Global (NASDAQ:TGL) and Akso Health Group (NASDAQ:AHG) Critical Analysis
defenseworld.net · Apr 8
Head-To-Head Contrast: NextPlat (NASDAQ:NXPL) versus Akso Health Group (NASDAQ:AHG)
defenseworld.net · Mar 29
Financial Contrast: NextPlat (NASDAQ:NXPL) vs. Akso Health Group (NASDAQ:AHG)
defenseworld.net · Mar 19
Akso Health Group (NASDAQ:AHG) Shares Gap Up – Still a Buy?
defenseworld.net · Mar 15
Akso Health Group Announces Launch of Exploratory Global Patient Support Initiative
prnewswire.com · Feb 3
Akso Health Group (NASDAQ:AHG) Shares Gap Up – What’s Next?
defenseworld.net · Jan 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.